FDA Commissioner Marty Makary resigns after tumultuous tenure

+ Accessibility links Skip to main content Keyboard shortcuts for audio player Open Navigation Menu --> Newsletters NPR Shop Close Navigation Menu Home News Expand/collapse submenu for News National World Politics Business Health Science Climate Race Culture Expand/collapse submenu for Culture Books Movies Television Pop Culture Food Art & Design Performing Arts Life Kit Gaming Music Expand/collapse submenu for Music Tiny Desk New Music Friday All Songs Considered Music Features Live Sessions Podcasts & Shows Expand/collapse submenu for Podcasts & Shows Daily Morning Edition Weekend Edition Saturday Weekend Edition Sunday All Things Considered Up First Here & Now NPR Politics Podcast Featured Wait Wait...Don't Tell Me!

+ Fresh Air Wild Card with Rachel Martin It's Been a Minute Planet Money Get NPR+ More Podcasts & Shows Search Newsletters NPR Shop Tiny Desk New Music Friday All Songs Considered Music Features Live Sessions About NPR Diversity Support Careers Press Ethics FDA Commissioner Marty Makary resigns after tumultuous tenure After a tumultuous 13 months at the helm of the U.S.

+ National FDA Commissioner Marty Makary resigns after tumultuous tenure May 13, 20264:46 AM ET Heard on Morning Edition By Sydney Lupkin , Michel Martin FDA Commissioner Marty Makary resigns after tumultuous tenure Listen &middot; 3:07 3:07 Transcript Toggle more options Download Embed Embed "> <iframe src="https://www.npr.org/player/embed/nx-s1-5819861/nx-s1-9768101" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player"> Transcript After a tumultuous 13 months at the helm of the U.S. Food and Drug Administration, Marty Makary has resigned. Sponsor Message LEILA FADEL, HOST: The commissioner of the Food and Drug Administration has resigned. Dr. Marty Makary told President Trump he was leaving Tuesday after 13 tumultuous months on the job. In a few minutes, we'll hear from a head of the FDA in Trump's first term about Makary's tenure. First, the details.

+ MICHEL MARTIN, HOST: NPR pharmaceuticals correspondent Sydney Lupkin is here to talk about the change. Good morning, Sydney. SYDNEY LUPKIN, BYLINE: Good morning. MARTIN: So why is this happening? LUPKIN: Well, I'm told the final straw for Makary was White House pressure to OK flavored vapes, something he did not agree with. That's according to a federal health official familiar with management of the agency but who wasn't authorized to speak publicly. The pressure has been building for a while. He had survived a series of controversies. Makary was definitely disrupting the agency, which is really in line with what the rest of the Trump administration has been trying to do to the federal government, and he made a lot of people mad. At times, Makary angered the Make America Healthy Again movement for not pushing the MAHA agenda fast enough or hard enough, and he upset people wanting a more predictable approach to regulation at the FDA. MARTIN: Can you give us some examples? LUPKIN: Oh, sure. For example, people who support the MAHA movement were upset when the agency approved updated COVID-19 vaccines last year. He also disappointed people who oppose abortion by approving a second generic version of mifepristone. Drugmakers and patient groups who want a consistent and predictable FDA were unhappy with the agency's reversals on experimental drugs and vaccines. Makary made some policy changes without convening the typical FDA advisory committees of outside experts. These committees have a lot of rules around them to make sure they're not biased, and they're typically convened before big agency decisions. It's a way to build public trust. And Makary didn't do that before changing the safety warnings on hormone replacement therapies. At the time, he called the committees bureaucratic, conflicted and expensive. So even though medical groups had long wanted those safety labels changed, they didn't like the way Makary did it. MARTIN: So what are people saying now that Makary is out? LUPKIN: In a post on Truth Social, President Trump thanked Makary for doing a great job. But Dr. Ben Rome, a physician and health policy researcher at Brigham and Women's Hospital in Boston, says he's glad to see Makary go. BEN ROME: I think the last year has been an unmitigated disaster for the FDA. So there has been a lot of changes to regulatory processes that have totally undermined the FDA's independent abilities and have introduced political interference into the process. LUPKIN: There's also been a big exodus of career staff. That's in addition to the mass firings that took place just after Makary was confirmed last year. Rome says he hopes the next person will right the ship, but he's worried. MARTIN: So speaking of that, who is the next person that we think will lead the FDA? LUPKIN: That would be Kyle Diamantas. Trump announced that he'll be the acting commissioner. Diamantas had been the deputy commissioner for food, overseeing nutrition and human food safety. He's a lawyer, not a medical doctor. But the administration has struggled to get some of its health picks confirmed by the Senate, so it may be a while before there's a permanent commissioner. MARTIN: That is NPR's pharmaceuticals correspondent Sydney Lupkin. Sydney, thank you. LUPKIN: You bet. Copyright &copy; 2026 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information. Accuracy and availability of NPR transcripts may vary. Transcript text may be revised to correct errors or match updates to audio. Audio on npr.org may be edited after its original broadcast or publication. The authoritative record of NPR’s programming is the audio record. Facebook Flipboard Email Read & Listen Home News Culture Music Podcasts & Shows Connect Newsletters Facebook Instagram Press Public Editor Corrections Transcripts Contact & Help About NPR Overview Diversity NPR Network Accessibility Ethics Finances Get Involved Support Public Radio Sponsor NPR NPR Careers NPR Shop NPR Extra Terms of Use Privacy Your Privacy Choices Text Only Sponsor Message Sponsor Message Become an NPR sponsor (function () { var loadPageJs = function () { (window.webpackJsonp=window.webpackJsonp||[]).push([[22],{1168:function(e,n,c){e.exports=c(321)},321:function(e,n,c){"use strict";c.p=NPR.serverVars.webpackPublicPath,Promise.all([c.e(1),c.e(2),c.e(3),c.e(4),c.e(82)]).then(function(e){c(3),c(1141),c(116),c(95),c(52),c(492),c(239),c(102),c(104),c(1142),c(144),c(1143),c(238),c(48),c(1144)}.bind(null,c)).catch(c.oe)}},[[1168,0]]]); }; if (document.readyState === 'complete') { loadPageJs(); } else { window.addEventListener('load', function load() { window.removeEventListener('load', load, false); loadPageJs(); }); } })();